Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 147,760 Shares

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 147,760 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $21.13, for a total transaction of $3,122,168.80. Following the completion of the transaction, the director directly owned 1,106,036 shares of the company’s stock, valued at $23,370,540.68. The trade was a 11.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 1.6%

Shares of Dyne Therapeutics stock opened at $20.94 on Friday. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -6.50 and a beta of 1.09. The firm’s 50 day simple moving average is $18.45 and its two-hundred day simple moving average is $18.11.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the company earned ($1.05) EPS. Analysts predict that Dyne Therapeutics, Inc. will post -3 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on DYN. TD Cowen initiated coverage on Dyne Therapeutics in a research note on Friday. They set a “buy” rating on the stock. Wall Street Zen raised shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Institutional Trading of Dyne Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DYN. T. Rowe Price Investment Management Inc. raised its position in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock valued at $343,085,000 after acquiring an additional 14,727,667 shares in the last quarter. Orbis Allan Gray Ltd purchased a new stake in Dyne Therapeutics in the 4th quarter worth approximately $93,926,000. Adage Capital Partners GP L.L.C. purchased a new stake in Dyne Therapeutics in the 2nd quarter worth approximately $30,378,000. Perceptive Advisors LLC boosted its position in Dyne Therapeutics by 543.7% in the 4th quarter. Perceptive Advisors LLC now owns 3,478,944 shares of the company’s stock worth $68,048,000 after purchasing an additional 2,938,500 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Dyne Therapeutics by 572.9% during the 3rd quarter. Marshall Wace LLP now owns 3,013,377 shares of the company’s stock worth $38,119,000 after purchasing an additional 2,565,570 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.